dacarbazine + interferon alpha + thymosin-alpha-1

This drug is a combination therapy consisting of dacarbazine, interferon alpha, and thymosin-alpha-1 used primarily for the treatment of metastatic melanoma. Dacarbazine is a chemotherapeutic agent that acts as an alkylating agent causing DNA damage leading to cancer cell death. Interferon alpha is an immunomodulatory cytokine that enhances immune response against tumor cells by activating immune effector cells and modulating antigen presentation. Thymosin-alpha-1 is a synthetic peptide hormone that potentiates T cell-mediated immune responses by enhancing effector T-cell function, stimulating interleukin-2 production, increasing macrophage antigen presentation efficiency, and modulating dendritic cell activity through toll-like receptor pathways. The combination aims to improve antitumor efficacy by combining direct cytotoxic effects (dacarbazine) with enhanced immune activation (interferon alpha and thymosin-alpha-1). Clinical studies have shown improved tumor response rates and progression-free survival in metastatic melanoma patients treated with this combination compared to dacarbazine plus interferon alone without additional toxicity[1][4][5][7].

Brand names

Zadaxin

Other names

dacarbazine + IFN-alpha + thymosin alpha 1DTIC + IFN-alpha + Tα1